Illumina Falls as Growth Targets Fail to Impress Investors.

Illumina Inc.'s shares fell after its plan to increase sales through easier DNA sequencing and improved data analysis failed to impress investors. The company's strategy aims for sales growth of 8% to 9% by 2027 and earnings per share growth of at least 10% over the next three years. Illumina also announced a partnership with the Broad Institute of MIT and Harvard. The CEO wants to revive the core business after a failed takeover attempt and a period of flat revenue. Illumina dominates the market for DNA decoding machines and is looking for new ways to offset sales decline. The company has seen a slowdown in its China business and expects revenue to decline this year. The CEO envisions a future where genomic sequencing becomes routine in medical care. [Extracted from the article]